News & Events

Phosphorex Exhibits at ASGCT 2026

Phosphorex Participates in the LNP Formulation & Process Development Summit 2026

LNP Alliance Launches New Website Focused on Advancing LNP Innovation and Collaboration

Phosphorex Appoints Jerry Williamson as Chief Executive Officer

HOPKINTON, Mass., Sept. 19, 2022 /PRNewswire/ — Followi capital investment from Ampersand Capital Partners, Phosphorex, a drug contract developm e nt and manufacturing organization (“CDMO”) providin polymer / lipid nanoparticles , announced today the appointment of Jarl Executive Officer.

Phosphorex, NOF CORPORATION, NeoSome Life Sciences, NanoImaging Services, and Envol Biomedical Unite to Form the LNP Alliance—Accelerating Lipid Nanoparticle Drug Development

Hopkinton, MA – May 8, 2025 – In a groundbreaking collaboration, Phosphorex, NOF CORPORATION, NeoSome Life Sciences, NanoImaging Services (NIS), and Envol Biomedical have joined forces to establish the LNP Alliance, a strategic partnership dedicated to advancing lipid nanoparticle (LNP) technology and accelerating the development of next-generation therapeutics.

Phosphorex Welcomes NOF CORPORATION as Shareholder and Strategic Partner

Hopkinton, MA and Tokyo – August 9, 2024– Phosphorex, a drug delivery-focused contract development and manufacturing organization (“CDMO”) backed by Boston-based private equity firm Ampersand Capital Partners, announced today that NOF CORPORATION has completed a strategic investment into the company.